The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut–lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut–lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research

Related Links:

We present a case of a 51 ‐year‐old Japanese woman diagnosed with eosinophilic granulomatous polyangiitis (EGPA), a rare vasculitis that can occur in patients with eosinophilia and history of asthma, allergic rhinitis, and sinusitis, with immunoglobulin (Ig) G4 hypergammaglobulinaemia and salivary gland swelling. AbstractA 51 ‐year‐old woman was admitted to our hospital for cough, fever, purpura in the legs, and salivary gland swelling. Six years ago, she had been diagnosed with bronchial asthma and was treated with a combination of inhaled corticosteroid and long‐acting beta2‐agonist. Blood examination showed ...
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research
There is an urgent need to share expertise and offer emergency guidance for breast radiation therapy (RT) during the COVID-19 (Coronavirus) pandemic. As per the World Health Organisation (WHO) statement, our aim and obligation should be “to stop, contain, control, delay and reduce the impact of this virus at every opportunity”. In our roles as healthcare professionals and/or breast cancer experts this translates to minimising exposure of our patients to COVID-19 without compromising oncological outcome.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Editorial Source Type: research
Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging [1]. The UK environment is well placed to conduct such trials; the NCRI prostate cancer CSG wished to benchmark current UK imaging availability and practice to inform future national trials.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) [1]. A recent retrospective study [2] and data from the UK Stampede control arm [3] suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: To assess the benefits and risks of co-administering maintenance prednisolone with docetaxel and androgen-deprivation therapy (ADT) in hormone sensitive metastatic prostate cancer (HSMPC).
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: As doctors we are required to take consent for radiotherapy; we typically take written consent [1]. We must tell a patient if a treatment might result in a serious adverse outcome, even if the likelihood is very small [2]. As many cancer centres move towards tumour site-specific consent forms for prostate radiotherapy we wanted to ascertain if there was consensus.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
In this study, we describe our experience with both drugs at the Diana Princess of Wales Hospital (DPoW), Grimsby.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Synchronous chemotherapy with mitomycin C and 5-FU with radiotherapy may have an additional benefit over radiotherapy alone [1]. We looked into the rate of recurrence and median overall survival between these two groups of patients.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Conclusions: Peroral arsenic has little effect on local airway immune responses to bacteria but compromises respiratory epithelial barrier integrity, increasing systemic translocation of inhaled pathogens and small molecules. Received: 09 March 2017 Revised: 14 August 2017 Accepted: 16 August 2017 Published: 28 September 2017 Address correspondence to M.B. Fessler, National Institute of Environmental Health Sciences, 111 T.W. Alexander Dr., P.O. Box 12233, Maildrop D2-01, Research Triangle Park, NC 27709 USA. Telephone: (919) 541-3701. Email: *Current address: UN...
Source: EHP Research - Category: Environmental Health Authors: Tags: Research Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Cancer | Cancer & Oncology | Chronic Obstructive Pulmonary | Cystic Fibrosis | Lung Cancer | Microbiology | Study